Can bisoprolol be used to treat stable supraventricular tachycardia in a woman who is 35 weeks pregnant?

Bisoprolol for Stable SVT at 35 Weeks Pregnancy

Bisoprolol is not specifically recommended in pregnancy guidelines for SVT management, and you should use metoprolol or propranolol instead, as these beta-blockers have the strongest evidence and guideline support for both acute and ongoing SVT treatment in pregnancy. 1

Why Not Bisoprolol?

The major pregnancy SVT guidelines from ACC/AHA/HRS explicitly recommend metoprolol and propranolol as the preferred beta-blockers, with Class I and IIa recommendations respectively 2, 1. Bisoprolol is notably absent from these recommendations despite being mentioned in other cardiac contexts during pregnancy 3, 4, 5.

Key Evidence Hierarchy:

• Metoprolol: Class I recommendation (Level B evidence) for prophylactic therapy 2
• Propranolol: Class IIa recommendation (Level B evidence) for prophylactic therapy 2
• Bisoprolol: Not mentioned in SVT pregnancy guidelines 2, 1

Recommended Approach at 35 Weeks

At 35 weeks gestation (third trimester), you are past the critical first-trimester teratogenic window, making beta-blocker use more acceptable:

For Acute Conversion:

1. First-line: Vagal maneuvers (Class I) 1
2. Second-line: IV adenosine (Class I) 1
3. Third-line: IV metoprolol or propranolol (Class IIa) 1
4. If unstable: Synchronized cardioversion (Class I) 1

For Ongoing Management:

Metoprolol or propranolol are the evidence-based choices (Class IIa) 1. These agents have:

• Decades of safety data in pregnancy
• Established efficacy for SVT prophylaxis
• Known side effect profiles

Critical Safety Considerations

Beta-Blocker Risks in Late Pregnancy:

All beta-blockers carry potential risks at 35 weeks:

• Intrauterine growth retardation (though less concerning in third trimester) 1
• Fetal bradycardia and hypoglycemia (rare, often related to fetal distress) 2
• Neonatal monitoring required after delivery for approximately 48 hours 6

Atenolol Warning:

Avoid atenolol (Class III recommendation) due to pronounced growth retardation risk, especially with earlier/longer exposure 2, 1, 2, 1. This serves as a cautionary tale for using non-recommended beta-blockers.

Why Metoprolol/Propranolol Over Bisoprolol?

1. Extensive pregnancy experience: Metoprolol and propranolol have been used for "many decades" with well-documented outcomes 1

2. Guideline-endorsed: Explicitly recommended by 2003 and 2015 ACC/AHA/ESC guidelines 2, 1

3. Beta-1 selectivity: Both metoprolol and bisoprolol are beta-1 selective, theoretically causing less uterine relaxation interference 2. However, only metoprolol has the pregnancy SVT evidence base.

4. Bisoprolol pregnancy data: Limited to case reports in other cardiac conditions (cardiac sarcoidosis, tachycardia-induced cardiomyopathy) 4, 5, not SVT-specific evidence

Practical Implementation

Use metoprolol as first choice:

• Start with lowest effective dose
• Monitor maternal heart rate and blood pressure
• Arrange fetal monitoring
• Plan for neonatal observation post-delivery (48 hours minimum) 6

Alternative if metoprolol contraindicated:

• Propranolol (slightly lower recommendation class but still guideline-supported)
• Digoxin (Class I for prophylaxis) 2
• Sotalol, flecainide, or verapamil (Class IIa/IIb) 1

Common Pitfall

Do not assume all beta-blockers are equivalent in pregnancy. The differential outcomes with atenolol demonstrate that individual agents have distinct risk profiles 1. Stick with guideline-recommended agents that have established safety records rather than extrapolating from non-pregnancy data.